Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

• Market Cap: AU$46.56M
• Dividend Yield: N/A
• Average Volume (3M): 306.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: N/A
• EPS Growth: -672.73%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 332,575,700
• 10 Day Avg. Volume: 291,172
• 30 Day Avg. Volume: 306,603
• PEG Ratio: 0.01
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: AU$0.13 ▲(34.00% Upside)

The score is held back primarily by weak fundamentals—revenue collapse, ongoing losses, and negative/free cash flow indicating continued cash burn—partly offset by a debt-free balance sheet. Technicals are supportive with price above major moving averages and positive MACD, but overbought momentum (high RSI/Stoch) adds near-term risk. Valuation is constrained by negative earnings and no dividend support.

Positive Factors

Debt-free balance sheet

A zero-debt capital structure materially reduces financial risk and interest burden, giving management more strategic flexibility. Over the medium term this supports survival through R&D cycles, eases partnership negotiations, and lowers bankruptcy risk compared with leveraged peers.

Focused neuroscience R&D

A clear, specialized scientific focus builds durable technical expertise and IP potential. In neuroscience, successful assets can command high pricing or attractive partnerships/licensing, so a concentrated pipeline can generate outsized long-term value if candidates progress through trials.

Positive equity position and solvency

Sustained positive equity indicates a solvency cushion that supports continued operations and reduces immediate pressure to restructure. Combined with the debt-free profile, this gives the company runway to pursue clinical milestones or partnerships before needing dilutive funding events.

Negative Factors

Revenue collapse

A full-year revenue collapse removes an important funding channel and reflects weak commercial traction. Over the medium term this increases reliance on external financing or licensing, reduces bargaining leverage with partners, and makes progress toward self-sustaining operations uncertain.

Persistent operating losses

Recurring operating deficits erode shareholder value and require continual capital injections. Persisting losses limit the firm's ability to internally finance development, raise questions about long-term profitability of the business model, and heighten dilution risk for investors.

Weak cash generation and cash burn

Consistent negative operating and free cash flow indicates ongoing cash burn tied to R&D and limited internal funding capacity. Over months this forces dependence on external capital, potentially at unfavorable terms, and constrains strategic options like larger trials or commercial launches.

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.

How the Company Makes Money

Neuroscientific Biopharmaceuticals Ltd. generates revenue primarily through the development and commercialization of its proprietary pharmaceutical products. The company's key revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from product sales. NSB may also engage in research collaborations and partnerships with academic institutions and research organizations to advance its drug development programs. Additionally, the company might receive grants and funding from government and non-government organizations to support its research initiatives.

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Financial performance is weak: revenue volatility includes a collapse to zero in 2025, profitability is persistently negative (recurring operating losses), and cash flow shows ongoing cash burn with deterioration in 2025. The main offset is a strong solvency profile with zero reported debt and positive equity.

Income Statement

Revenue has been highly volatile and recently collapsed to zero in 2025 (annual), following declines from 2023 to 2024. Profitability is weak: the company posted large operating losses across the period (negative EBIT/EBITDA every year shown), and 2025 returned to a sizable net loss after a small net profit in 2024. Overall, the income statement reflects a business still in heavy investment mode with limited visibility to consistent revenue generation.

Balance Sheet

The balance sheet is a relative strength: total debt is reported as zero across all periods, reducing financial risk and interest burden. Equity remains positive, and total assets are largely equity-funded; however, equity levels have been volatile (notably higher in 2021 and 2025 vs. 2023–2024), and returns on equity are mostly negative due to recurring losses (except 2024). Net-net, solvency looks solid, but shareholder value creation is inconsistent.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow and free cash flow are negative in most years (including a sharp deterioration in 2025), with only a modest positive year in 2024. The pattern suggests ongoing cash burn typical of early-stage biotech, increasing funding dependence despite low balance-sheet leverage.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	2.21M	4.95M	0.00	958.77K
Gross Profit	-92.78K	-92.78K	-91.34K	-57.85K	-64.92K	897.36K
EBITDA	-1.92M	-1.92M	-1.80M	-5.96M	-10.37M	-3.12M
Net Income	-1.85M	-1.85M	324.21K	-1.07M	-10.44M	-3.18M
Balance Sheet
Total Assets	16.96M	16.96M	5.44M	5.29M	7.74M	14.83M
Cash, Cash Equivalents and Short-Term Investments	7.27M	7.27M	4.95M	4.91M	7.22M	14.16M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	149.22K	149.22K	85.68K	597.36K	2.22M	223.41K
Stockholders Equity	16.81M	16.81M	5.35M	4.69M	5.52M	14.60M
Cash Flow
Free Cash Flow	-941.33K	-941.33K	42.43K	-2.30M	-6.95M	-2.63M
Operating Cash Flow	-941.33K	-941.33K	44.25K	-2.30M	-6.94M	-2.60M
Investing Cash Flow	-36.04K	-36.04K	-1.81K	0.00	-3.87K	-29.88K
Financing Cash Flow	3.29M	3.29M	0.00	0.00	0.00	13.51M

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Neutral. The current price of 0.1 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.12, and below the 200-day MA of 0.13, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.62 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPL	53 Neutral	AU$172.17M	-17.08	-41.51%	―	-40.74%	-21.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTX	50 Neutral	AU$77.81M	-8.13	-49.72%	―	―	10.78%
NSB	49 Neutral	AU$46.56M	-11.11	-16.65%	―	―	-672.73%
CYP	46 Neutral	AU$83.11M	-7.74	-138.54%	―	―	16.61%
ILA	43 Neutral	AU$113.00M	-18.58	-90.37%	―	―	26.38%
ADO	40 Underperform	AU$40.14M	-5.20	-159.86%	―	110.44%	35.90%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace

NeuroScientific Biopharmaceuticals has advanced clinical and operational development of its StemSmart™ mesenchymal stem cell platform during the December 2025 quarter, with a particular focus on treating patients with severe, treatment-resistant fistulising Crohn’s disease through Australia’s Special Access Scheme. The company reported that three of four patients in the first cohort achieved a clinical response, providing early validation of the technology and informing the design of a planned Phase 2 trial in refractory Crohn’s disease expected to start in 2026. In parallel, NeuroScientific has appointed a Clinical & Scientific Advisory Board, progressed manufacturing technology transfer and scale-up with Q-Gen to bolster future clinical and supply readiness, and ended the quarter with approximately $6.4 million in cash, supporting its near-term clinical development plans and reinforcing its positioning as an emerging player in advanced cell therapies for inflammatory bowel disease.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients

NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a successful clinical response, while the fourth patient showed a partial response with ongoing assessment. The strong outcomes in this hard-to-treat patient group are being used to shape the design of later-phase clinical trials expected to begin in the second half of 2026, underpin Phase 2 start-up activities including commercial manufacturing and regulatory planning, and support the company’s strategy to establish a foothold in the multibillion-dollar global Crohn’s disease market while expanding StemSmart™ as a broader platform therapy for chronic inflammatory indications.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific Biopharmaceuticals Advances Therapeutics for Crohn’s Disease and Neuroprotection

NeuroScientific Biopharmaceuticals Ltd announced the results of its Annual General Meeting, where all resolutions were determined by a poll. The company is advancing its proprietary StemSmart technology to target fistulising Crohn’s disease, aiming for Phase 2 clinical trials to evaluate safety and efficacy. This initiative supports NSB’s strategy to obtain regulatory approval for its MSC therapy in Australia and internationally. Additionally, NSB’s EmtinB™ compound, which promotes neuroprotection and neuroregeneration, has shown promising preclinical results, demonstrating safety and specificity for its target receptor.

NeuroScientific Biopharmaceuticals to Host Investor Webinar on Strategic Advances

NeuroScientific Biopharmaceuticals Ltd. announced an upcoming investor webinar where CEO Nathan Smith will discuss the company’s recent performance and future milestones. The company is prioritizing its StemSmart technology for Crohn’s disease, aiming for Phase 2 trials, and is working on EmtinB™, a compound for neuroprotection, reflecting its commitment to innovative treatments in the biotechnology sector.

NeuroScientific Advances StemSmart™ Therapy for Crohn’s Disease

NeuroScientific Biopharmaceuticals has initiated treatment for the fourth patient under its Special Access Program using its StemSmart™ MSC therapy for fistulising Crohn’s disease, marking progress towards a Phase 2 clinical trial planned for 2026. This program provides critical real-world data to inform the trial design and offers a potential new therapeutic option for patients with severe, treatment-resistant Crohn’s disease, addressing a significant unmet medical need.

NeuroScientific Biopharmaceuticals Establishes Advisory Board to Drive Innovation

NeuroScientific Biopharmaceuticals Ltd has announced the formation of a Clinical & Scientific Advisory Board to guide its scientific innovation and product development. The board, led by Chief Medical Officer Dr. Catherine Cole, includes experts in nephrology, gastroenterology, and respiratory medicine. This strategic move aims to enhance the company’s clinical strategy and address unmet medical needs in immune-mediated inflammatory disorders.